Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star
Shots:
- F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star
- Merck KGaA will be responsible for the development and commercialization of the preclinical program and exercised its first license option in May 2019 that brought the first program from the collaboration into its pipeline
- The companies have agreed to the licensing terms for the inclusion of two additional preclinical programs under the existing partnership
Ref: Businesswire | Image: Merck KGaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com